As the deficiency of NTHL1 can lead to polyposis and carcinoma, and the tumor phenotypes are broad spectrum, Grolleman et al. suggested that biallelic NTHL1 mutation should be included in the surveillance guidelines for MAP [45]. This evidence concerns the gene NTHL1 and carcinoma.